Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| AMC-112 | AMC | Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| AMC-115 | AMC | Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AIDS Malignancy Consortium | Adult CIRB - Late Phase Emphasis | Available to Open | |
| AMC-S005 | AMC | Biospecimen Collection and Donation to the AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials | Adult CIRB - Late Phase Emphasis | Available to Open | |
| ANBL00B1 | COG | Neuroblastoma Biology Studies | Pediatric CIRB | Available to Open | |
| ANBL00P3 | COG | A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone | Pediatric CIRB | Completed | |
| ANBL0322 | COG | A Phase II Study of hu14.18-IL2*(BB-IND-9798) In Children with Recurrent or Refractory Neuroblastoma | Pediatric CIRB | Completed | |
| ANBL0421 | COG | A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma: A Groupwide Phase II Study | Pediatric CIRB | Completed | |
| ANBL0531 | COG | Response- and Biology-Based Therapy for Intermediate-risk Neuroblastoma: A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ANBL0532 | COG | Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma: A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ANBL0931 | COG | A Comprehensive Safety Trial of Chimeric Antibody 14.18 (ch14.18) with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy | Pediatric CIRB | Completed |